Asymptomatic Carotid Lesions and Cognitive Impairment: Does Intervention Play a Role?

This study was designed to determine the effect of carotid endarterectomy/angioplasty on early (baseline vs. 3 months) and late (baseline vs. >5 months) cognitive function in patients with asymptomatic lesions. This systematic research included 31 non-randomized studies. Regarding the immediate post-operative period, 24 of these papers reported significant improvement in cognitive function; one study reported significant deterioration;<a href="https://solaci.org/en/2021/09/20/asymptomatic-carotid-lesions-and-cognitive-impairment-does-intervention-play-a-role/" title="Read more" >...</a>

The Most Read Articles in August in Interventional Cardiology

01- Best Revascularization Strategy in Patients with Left Ventricular Deterioration Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy.  Read also HERE 02- SOLACI Renewed Authorities During the SOLACI-CACI 2021 Congress After a massive event attended by thousands of people, the Latin American Society of Interventional Cardiology renewed its authorities for<a href="https://solaci.org/en/2021/09/10/the-most-read-articles-in-august-in-interventional-cardiology/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

HOST-EXAM: The Study that Challenges Aspirin as Long-Term Antiplatelet Therapy

The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel. Over the course of four years, 5438 patients (mean<a href="https://solaci.org/en/2021/09/10/host-exam-the-study-that-challenges-aspirin-as-long-term-antiplatelet-therapy/" title="Read more" >...</a>

ESC 2021 | COVERT-MI: Colchicine Attempts to Reduce Infarct Size

Colchicine does not offer protection against myocardial injury in ST-segment elevation myocardial infarction when administered during reperfusion and in the following five days, according to the randomized study COVERT-MI. It could even generate signs of damage with 3x the amount of thrombi in the ventricle. The results presented at the European Society of Cardiology 2021<a href="https://solaci.org/en/2021/09/01/esc-2021-covert-mi-colchicine-attempts-to-reduce-infarct-size/" title="Read more" >...</a>

ESC 2021 | RIPCORD-2: Routine FFR Evaluation of All Epicardial Vessels During Angiography

The predecessor of this research—RIPCORD, published in 2014—showed that using fractional flow reserve (FFR) changes the treatment strategy in about 25% of patients. That marked the rise of FFR. In fact, the DEFER, FAME, and FAME 2 studies offered results consistent with the original RIPCORD. In this research, authors tested the hypothesis of systematic use of<a href="https://solaci.org/en/2021/09/01/esc-2021-ripcord-2-routine-ffr-evaluation-of-all-epicardial-vessels-during-angiography/" title="Read more" >...</a>

ESC 2021 | TOMAHAWK: Angiography After Resuscitated Patients from Out-Of-Hospital Cardiac Arrest with No ST Elevation.

What triggered this study was a long unanswered question: should patients successfully resuscitated from an out-of-hospital cardiac arrest presenting a non-STEMI ECG be immediately taken to the cath lab?  In response to this question the TOMAHAWK randomized 554 out-of-hospital resuscitated patients without electrocardiographic evidence of ST-segment elevation patients to immediate angiography (n=281) vs intensive care<a href="https://solaci.org/en/2021/08/31/esc-2021-tomahawk-angiography-after-resuscitated-patients-from-out-of-hospital-cardiac-arrest-with-no-st-elevation/" title="Read more" >...</a>

ESC 2021 | ACST-2: CAS vs endarterectomía en pacientes asintomáticos

ESC 2021 | ACST-2: CAS vs Endarterectomy in Asymptomatic Patients

The ACST-2 was designed to compare long-term outcomes of carotid artery stenting (CAS) vs carotid endarterectomy (CEA) in patients with asymptomatic stenosis.  Prior to this study we had the German registry including 18,000 patients undergoing CAS and 86,000 receiving CEA between 2014 and 2019. At 30 days, disabling stroke rate was 0.7% for both strategies.<a href="https://solaci.org/en/2021/08/31/esc-2021-acst-2-cas-vs-endarterectomy-in-asymptomatic-patients/" title="Read more" >...</a>

The Most Read Articles in Interventional Cardiology of July

01- Novel DES Technology Promises to Become the Next DES Generation The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Read more HERE 02- The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use? Here is the third Fellow’s<a href="https://solaci.org/en/2021/08/25/the-most-read-articles-in-interventional-cardiology-of-july/" title="Read more" >...</a>

IVUS vs OCT para guiar la angioplastia ¿Cuál elegir?

How Bad is Malapposition? OCT Findings and Events

Most post-angioplasty findings with optical coherence tomography (OCT) were not associated with clinical adverse events. Exceptions were small intra-stent area, and significant malapposition. Suboptimal findings after angioplasty are very common (almost expected), although their clinical implications are uncertain. This registry—recently published in JACC—was developed in an attempt to answer these questions. The analysis included a<a href="https://solaci.org/en/2021/08/13/how-bad-is-malapposition-oct-findings-and-events/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES. The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs<a href="https://solaci.org/en/2021/08/13/the-long-marathon-of-ultrathin-vs-2nd-generation-thin-strut-des/" title="Read more" >...</a>